PHIO PHARMACEUTICALS CORP (PHIO) Fundamental Analysis & Valuation

NASDAQ:PHIO • US71880W5013

Current stock price

1.22 USD
+0.04 (+3.39%)
At close:
1.2 USD
-0.02 (-1.64%)
After Hours:

This PHIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. PHIO Profitability Analysis

1.1 Basic Checks

  • PHIO had negative earnings in the past year.
  • In the past year PHIO has reported a negative cash flow from operations.
  • In the past 5 years PHIO always reported negative net income.
  • In the past 5 years PHIO always reported negative operating cash flow.
PHIO Yearly Net Income VS EBIT VS OCF VS FCFPHIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -40.48%, PHIO is in line with its industry, outperforming 57.39% of the companies in the same industry.
  • PHIO has a better Return On Equity (-43.17%) than 68.91% of its industry peers.
Industry RankSector Rank
ROA -40.48%
ROE -43.17%
ROIC N/A
ROA(3y)-110.57%
ROA(5y)-88.07%
ROE(3y)-133.2%
ROE(5y)-105.54%
ROIC(3y)N/A
ROIC(5y)N/A
PHIO Yearly ROA, ROE, ROICPHIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • PHIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHIO Yearly Profit, Operating, Gross MarginsPHIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PHIO Health Analysis

2.1 Basic Checks

  • PHIO has more shares outstanding than it did 1 year ago.
  • PHIO has more shares outstanding than it did 5 years ago.
  • PHIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PHIO Yearly Shares OutstandingPHIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
PHIO Yearly Total Debt VS Total AssetsPHIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

  • PHIO has an Altman-Z score of -4.05. This is a bad value and indicates that PHIO is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -4.05, PHIO perfoms like the industry average, outperforming 42.42% of the companies in the same industry.
  • PHIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.05
ROIC/WACCN/A
WACCN/A
PHIO Yearly LT Debt VS Equity VS FCFPHIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 16.03 indicates that PHIO has no problem at all paying its short term obligations.
  • The Current ratio of PHIO (16.03) is better than 93.28% of its industry peers.
  • PHIO has a Quick Ratio of 16.03. This indicates that PHIO is financially healthy and has no problem in meeting its short term obligations.
  • PHIO has a better Quick ratio (16.03) than 93.28% of its industry peers.
Industry RankSector Rank
Current Ratio 16.03
Quick Ratio 16.03
PHIO Yearly Current Assets VS Current LiabilitesPHIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PHIO Growth Analysis

3.1 Past

  • PHIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.64%, which is quite impressive.
EPS 1Y (TTM)85.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • PHIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.91% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.37%
EPS Next 2Y35.74%
EPS Next 3Y23.91%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHIO Yearly Revenue VS EstimatesPHIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2023 20M 40M 60M
PHIO Yearly EPS VS EstimatesPHIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50K -100K -150K

More info and screens

Find the best growth stocksShow best growing peers

1

4. PHIO Valuation Analysis

4.1 Price/Earnings Ratio

  • PHIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHIO Price Earnings VS Forward Price EarningsPHIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHIO Per share dataPHIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • PHIO's earnings are expected to grow with 23.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.74%
EPS Next 3Y23.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHIO Dividend Analysis

5.1 Amount

  • No dividends for PHIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHIO Fundamentals: All Metrics, Ratios and Statistics

PHIO PHARMACEUTICALS CORP

NASDAQ:PHIO (3/20/2026, 8:16:56 PM)

After market: 1.2 -0.02 (-1.64%)

1.22

+0.04 (+3.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-13
Inst Owners8.85%
Inst Owner Change93.03%
Ins Owners6.01%
Ins Owner Change21.93%
Market Cap14.18M
Revenue(TTM)N/A
Net Income(TTM)-8.70M
Analysts82.86
Price Target14.28 (1070.49%)
Short Float %5.25%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.59%
Min EPS beat(2)4.14%
Max EPS beat(2)27.05%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)2.08%
EPS NQ rev (3m)2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)11.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-6.48
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS1.73
TBVpS1.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.48%
ROE -43.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-110.57%
ROA(5y)-88.07%
ROE(3y)-133.2%
ROE(5y)-105.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.03
Quick Ratio 16.03
Altman-Z -4.05
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)76.79%
Cap/Depr(5y)64.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.24%
EPS Next Y75.37%
EPS Next 2Y35.74%
EPS Next 3Y23.91%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.68%
EBIT Next 3Y-17.49%
EBIT Next 5YN/A
FCF growth 1Y33.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.84%
OCF growth 3YN/A
OCF growth 5YN/A

PHIO PHARMACEUTICALS CORP / PHIO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PHIO PHARMACEUTICALS CORP?

ChartMill assigns a fundamental rating of 3 / 10 to PHIO.


What is the valuation status for PHIO stock?

ChartMill assigns a valuation rating of 1 / 10 to PHIO PHARMACEUTICALS CORP (PHIO). This can be considered as Overvalued.


What is the profitability of PHIO stock?

PHIO PHARMACEUTICALS CORP (PHIO) has a profitability rating of 1 / 10.


How financially healthy is PHIO PHARMACEUTICALS CORP?

The financial health rating of PHIO PHARMACEUTICALS CORP (PHIO) is 7 / 10.